Moshe and Ivet join TWiV to discuss their finding that MIS-C is a consequence of a superantigen in the spike protein of SARS-CoV-2 that causes activation of a skewed population of T cell receptor bearing lymphocytes, leading to hyperinflammation.
On this episode of TWiV, Novavax COVID-19 vaccine demonstrates 90% overall efficacy, preventing an antigenically disruptive change during growth of influenza virus vaccine in chicken eggs, and MIS-C is driven by loss of the gut mucosal barrier.